Thyrocare Technologies Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 5,372,353 (50%) | — | ₹23,961 Cr |
| NII (HNI) | — | 1,611,707 (15%) | — | ₹7,188 Cr |
| Retail | — | 3,760,648 (35%) | — | ₹16,772 Cr |
| Σ Total | — | 10,744,708 (100%) | — | ₹479,214 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 33 | ₹14,718 |
| Retail (Max) | 13 | 429 | ₹191,334 |
| S-HNI (Min) | 14 | 462 | ₹206,052 |
| B-HNI (Min) | 67 | 2,211 | ₹986,106 |
Financial Statements Amount in Crore
| Metric | 31-Dec-15 | 31-Mar-15 |
|---|---|---|
| Revenue | 180 | 190 |
| Profit After Tax | 40 | 43 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- –
Company Overview
Incorporated in 2000, Thyrocare Technologie Ltd is one of the leading pan-India diagnostic chains and conduct an array of medical diagnostic tests and profiles of tests that helps in early detection and management of disorders and diseases.
They are India's first fully automated diagnostic laboratory having its strong presence in more than 2000 cities / towns in India and internationally. As of November 30, 2015, they offered 192 tests and 54 profiles of tests to detect a number of disorders, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility and various infectious diseases.
Their laboratory process over 30,000 sample and above 1 lakh investigations every day. Their profiles of tests include 17 profiles of tests administered under their 'Aarogyam' brand. Through wholly owned subsidiary, NHL, they operate a network of molecular imaging centers in New Delhi, Navi Mumbai and Hyderabad, focused on early and effective cancer monitoring.